Galapagos Begins Phase 2b/3 Clinical Trial of Filgotinib in Ulcerative Colitis Patients

Galapagos Begins Phase 2b/3 Clinical Trial of Filgotinib in Ulcerative Colitis Patients
Galapagos NV recently announced that it has dosed the first patient with ulcerative colitis (UC) in its SELECTION Phase 2b/3 clinical trial, investigating the efficacy and safety of two doses of filgotinib as a UC treatment. SELECTION  (NCT02914522) is investigating two doses of filgotinib (100 mg and 200 mg filgotinib once daily), compared to placebo, as an induction

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *